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on gene transfer efficiency to arterial and venous
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San Francisco, Calif
Objective: Adenoviral-mediated gene transfer to arterial and venous grafts has potential in the treatment of a number of
vascular diseases. Despite widespread use of these vectors to mediate gene transfer to blood vessel walls, the optimal
transduction conditions for each type of vessel has yet to be determined. Our objective was to study the effect of
adenoviral titer and instillation pressure on efficiency of gene transfer to arterial and venous grafts ex-vivo.
Methods: Jugular vein and carotid artery segments of 8 cm were harvested from Yorkshire Cross pigs. Tissue culture media
or different titers of an adenoviral vector encoding human placental alkaline phosphatase (hpAP) were instilled into
venous and arterial grafts at 0 mm Hg or 80 to 100 mm Hg of pressure and bathed externally in the same solution at
37° C for 30 minutes. The grafts were rinsed, opened longitudinally, and incubated in culture media at 37° C for 48
hours. Grafts were fixed and stained for hpAP transgene expression to quantitate percent luminal transduction or
homogenized for alkaline phosphatase (AP) activity to determine total transmural transduction.
Results: For venous grafts, the percent luminal area stained for hpAP was greatest with 108 plaque-forming units/mL at
0 mm Hg (81% 7%) and decreased with increasing titers (53% 9% at 109 pfu/mL and 44% 11% at 5 109 pfu/mL;
n 7; P < .05). No increase in percent luminal area stain was achieved with an instillation pressure of 80 to 100 mm Hg
at any viral titer. The inverse finding was observed in arterial grafts. For arterial grafts, the greatest percent luminal area
stained was achieved with 5  109 pfu/mL at 80 to 100 mm Hg (76%  7%). An instillation pressure of 80 to 100 mm
Hg increased the percent luminal area stained at 108 pfu/mL from 31%  9% to 66%  8% (n  8; P  .01). For venous
grafts, total AP activity peaked with 109 pfu/mL at 0 mm Hg and decreased with an instillation pressure of 80 to 100 mm
Hg (30.6  9.7 U/mg versus 10.9  2.5 U/mg; n  7; P < .01). However, for arterial grafts, total AP activity peaked
with 5  109 pfu/mL (0 mm Hg) and increased with an instillation pressure of 80 to 100 mm Hg (32.8  9.9 U/mg
versus 63.4  20.5 U/mg; n  8; P < .05).
Conclusion: High transduction efficiency can be achieved with adenoviral-mediated gene transfer of arterial and venous
grafts. Gene transfer with the vascular graft’s physiologic pressure conditions improved transduction efficiency for the
artery (80 to 100 mm Hg) and vein (0 mm Hg). Comprehensive analysis of adenoviral transduction conditions is
important to realize the full promise of adenoviral-mediated gene transfer. (J Vasc Surg 2002;36:263-70.)
Adenoviral-mediated gene transfer of vascular cells and
grafts holds promise because of the vector’s ability to infect
nonreplicating cells and because of their high transduction
efficiency after only brief exposure periods. Adenoviral-
mediated gene transfer of nonphosphorylatable retinoblas-
toma,1 tissue inhibitor of metalloproteinase-3,2 and induc-
ible nitric oxide synthase3 to vascular grafts has shown some
potential of this technique to inhibit intimal hyperplasia.
However, the methods of vascular graft gene transduction
have been variable. Numerous successful reports have used
various techniques for adenoviral-mediated gene transfer of
vascular grafts. Good transduction efficiency with adenovi-
ral vectors was achieved in rabbit aortas after they were
stretched longitudinally and pressurized to 150 mm Hg.4
Techniques for transfection of vein grafts have varied from
bathing the segment in an adenoviral vector solution for 24
hours5 or distending it to a physiologic dimension for 30
minutes.6
Because gene transfer to vascular cells and grafts is an
ongoing interest of our laboratory,7 our earlier investiga-
tions were concentrated on decreasing vascular allograft
rejection in porcine veins in-vivo. A profound inflammatory
reaction to the adenoviral vector occurred in the venous
grafts when we performed gene transfer with the tech-
niques derived from adenoviral-mediated gene transfer to
arterial grafts (data not published). In this study, we tested
the hypothesis that the optimal instillation pressure and
adenoviral titer is different for venous and arterial grafts. To
define the optimal transduction conditions, we determined
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the effect of different adenoviral titers and instillation pres-
sure on the percent luminal area stained and total transmu-
ral gene transfer in porcine arteries and veins ex-vivo.
MATERIALS AND METHODS
Adenoviral vectors. The replication incompetent ad-
enoviral vector used contained deletions of E1 and E3
regions and contained transgene for the human placental
alkaline phosphatase (AdhpAP) driven by the Rous sarcoma
virus promoter. The vector was a generous gift of Dr
Beverly L. Davidson (University of Iowa College of Medi-
cine). Propagation and purification of these vectors were
performed as described.8 Vector stocks were stored in
80° C and thawed immediately before use and were
diluted in tissue culture media to achieve a final concentra-
tion of 1  108 to 1  1010 plaque-forming units
(pfu)/mL for AdhpAP. The concentrations of all adenovi-
ral vectors were assayed with standard plaque assay tech-
niques. Tissue culture media used as a control solution were
composed of Roswell Park Memorial Institute medium
1640 supplemented with 10% heat inactivated porcine
serum, 1 mmol/L sodium pyruvate, 50 U/mL penicillin,
and 50g/mL streptomycin.
Animals. Sixty-four 8-cm segments of the jugular vein
and carotid arteries were harvested from 32 Yorkshire Cross
pigs killed for other studies not involving pharmacologic or
surgical manipulation of the carotid artery or jugular veins.
The care of animals complied with the Guide for the Care
and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, Commission on Life Sciences, National
Research Council, Washington, DC, National Academy
Press, 1996). All protocols were approved in accordance
with the Committee on Animal Research at the University
of California–San Francisco. The animals were anesthe-
tized, intubated, and ventilated for vascular graft harvest or
were killed less than 15 minutes before vascular graft har-
vest.
Preparation of vascular grafts. Immediately on har-
vest, the grafts were flushed with 4° C tissue culture media,
stored in media, and brought immediately to a separate
laboratory for adenoviral transduction. The time between
harvest and transduction ranged from 5 to 20 minutes.
Each vessel was transected in half (transversely) and thus
provided 128 segments for experimental conditions. Vas-
cular grafts were prepared for transfection with ligation of
the proximal end and all side branches. The distal end was
cannulated with a 24-gauge bulb tipped stainless steel
catheter for viral instillation. The catheter was filled with
heparinized saline solution connected and attached to a
pressure transducer. A solution containing culture media or
different titers of AdhpAP was instilled into venous and
arterial grafts at approximately 0 mm Hg or 80 to 100 mm
Hg of pressure. In the initial 2 to 3 minutes, the constancy
of pressure was rechecked with the three-way stop-cock and
the pressure transducer. After no change in pressure was
noted, a ligature would be placed on the vessel just inside to
the catheter to prevent leakage of the solution. The vessel
was placed in a tube filled with the identical solution
instilled in the vessels, and the whole tube was incubated in
a water bath at 37° C for 30 minutes. After incubation, the
vessels were evaluated for maintenance of wall tension and
shape. If a loss in pressure occurred, the segments were
discarded. After treatment and removal of 5 to 8 mm at
each end (after transfection), vascular grafts then were
rinsed in culture media, opened longitudinally, transected
in half, and placed in individual wells of a six-well plate
(leaving approximately 1.5 cm per segment per well). All
vessels were adequately covered with tissue culture media.
Grafts were incubated in culture media at 37° C, 95%
air/5% CO2, for 48 hours. Media were changed after 24
hours. Grafts then were rinsed in phosphate-buffered saline
solution and divided in half transversely. One half was fixed
in 4% paraformaldehyde and stained for heat-stable alkaline
phosphatase (AP) activity. The second half was snap frozen
and homogenized for AP activity.
Staining for human placental alkaline phosphatase
transgene expression. As previously described,9 briefly,
vascular grafts were embedded into paraffin blocks in a
transverse orientation. Five-micron sections were mounted
onto poly-l-lysine slides. The slides were deparaffinized in
three changes of xylene and then rehydrated with 100%,
95%, and 75% ethyl alcohol. Endogenous (heat-labile) AP
then was inactivated by incubating slides at 65° C for 60
minutes as we have previously shown in gene transfer
studies in-vivo with heat-stable AP as a reporter
gene.9Sections then were incubated in phosphate-buffered
saline solution containing a chromogenic substrate of
5-bromo-4-chloro-3-indolyl phosphate-p-toluidine (1
mg/mL) and nitro blue tetrazolium chloride (1 mg/mL)
for 19 hours. Sections were rinsed and counterstained with
hematoxylin and were photographed (200.) Dark blue-
purple staining signified positive staining of hpAP with
light microscopy. Percent luminal area stained was calcu-
lated with dividing the length of the positive luminal area
stained by the total length of the luminal surface area as
measured with an ocular gradicule and multiplying the
quotient by 100. Each box of the gradicule measured
0.0625 mm2 at magnification of 400. Two sections from
the mid portion of each graft were analyzed by a blinded
reader.
Determination of alkaline phosphatase activity.
Vessels were snap frozen in liquid nitrogen and ground into
a powder. The tissue was homogenized in 50 mmol/L
acetic acid. N-butanol was used to extract the AP from the
plasma membranes. The mixture was incubated for 2 hours
at room temperature, with mixing every 30 minutes, then
centrifuged at 1500 rpm for 5 minutes. The resulting
protein lysate in the aqueous phase was used for the enzyme
assay. A substrate buffer was prepped with 80-mg p-
nitrophenol phosphate in 10 mL to which 100L of pro-
tein lysate was added. This mixture was incubated for 30
minutes, and the production of p-nitrophenol by AP was
measured with reading the absorbance at 410 nm against a
blank. Total protein in vessel extracts was measured with
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the bicinchoninic acid protein assay (Pierce, Rockford, Ill),
with bovine serum albumin used as a standard. The AP
activity was reported as U/mg of protein.
Statistical analysis. All data are presented as mean 
standard error of the mean. Normally distributed data were
analyzed with repeated measures analysis of variance. Post
hoc intergroup comparisons were made with Fisher exact
test, with significance reported at P less than .05. Because
percentages are not normally distributed, the percent lumi-
nal area stained was analyzed with the Friedman test and
the Wilcoxon signed rank test, with significance reported at
P less than .05.
RESULTS
Efficacy of gene transfer to luminal cells. In jugular
vein grafts, the percent luminal area stained for hpAP
decreased as the viral titer increased (Fig 1, A, C, and E).
No positive staining was seen in control veins treated with
culture media during various experimental conditions (data
not shown). The percent luminal area stained was 81% 
7% when transduced with 1  108 pfu/mL of AdhpAP.
The percent luminal area stained significantly decreased
with increasing titers (53%  9% at 1  109 pfu/mL; n 
7; P .05; and 44% 11% at 5 109 pfu/mL; n 7; P
Fig 1. Representative photomicrographs of effect of adenoviral titer and instillation pressure on percent luminal area
stained on porcine venous grafts. Blue-purple stain represents positive stain for hpAP (original magnification, 200).
A, 108 pfu/mL at 0 mm Hg. B, 108 pfu/mL at 80 to 100 mm Hg. C, 109 pfu/mL at 0 mm Hg. D, 109 pfu/mL at
80 to 100 mm Hg. E, 5  109 pfu/mL at 0 mm Hg. F, 5  109 pfu/mL at 80 to 100 mm Hg.
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.05; Fig 2, A). Transduction efficiency of venous grafts at
an instillation pressure of 80 to 100 mm Hg did not result
in a change in the percent luminal area stained (Fig 1, B, D,
and F).
The carotid artery grafts that were transduced with
AdhpAP had increasing percent luminal area stained with
increasing titers of adenovirus that peaked at 5  109
pfu/mL (Fig 3, A, C, E, and G). No positive staining
was seen in control arteries (data not shown). The
percent luminal area stained was 31%  9% when trans-
duced with 1  108 pfu/mL of AdhpAP. The percent
luminal area stained increased significantly to 66%  4%
with a titer of 5  109 pfu/mL (n  6; P  .05; Fig 2, B).
An increase was seen in percent luminal area stained of the
carotid artery grafts with an instillation pressure consistent
with arterial physiologic pressure. However, statistical sig-
nificance was only achieved at the lowest titer of 1  108
pfu/mL. At that titer, percent luminal area stained in-
creased to 66% 8% at 80 to 100 mm Hg (n 8; P .01;
Fig 2, B).
Efficacy of gene transfer to graft wall. In both ve-
nous and arterial grafts, occasional cells were seen within
the media that stained positive for hpAP; however, no
significant difference was found with increasing adenoviral
titers nor instillation pressure (data not shown). A trend
was seen towards an increase in percent adventitial stain,
with an increase in adenoviral titer in both venous and
arterial grafts that did not reach statistical significance (Fig
4, A and B, respectively).
All jugular vein grafts that were transduced with Adh-
pAP had increased AP activity over control grafts. The AP
activity of control veins was 0.9  0.2 U/mg at 0 mm Hg
Fig 2. Effect of adenoviral titer and instillation pressure on percent luminal area stained of porcine venous and arterial
grafts. A, Venous grafts, *P  .05 versus 109 pfu/mL and 5  109 pfu/mL at 0 mm Hg. B, Arterial grafts, *P  .05
versus 108 pfu/mL at 0 mm Hg and P  .05 versus 108 pfu/mL at 0 mm Hg.
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Fig 3. Representative photomicrographs of effect of adenoviral titer and instillation pressure on percent luminal area
stained on porcine arterial grafts. Blue-purple stain represents positive stain for hpAP (original magnification 200). A,
108 pfu/mL at 0 mm Hg. B, 108 pfu/mL at 80 to 100 mm Hg. C, 109 pfu/mL at 0 mm Hg. D, 109 pfu/mL at 80
to 100 mm Hg. E, 5 109 pfu/mL at 0 mm Hg. F, 5 109 pfu/mL at 80 to 100 mm Hg. G, 1010 pfu/mL at 0 mm
Hg. H, 1010 pfu/mL at 80 to 100 mm Hg.
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and 0.8  0.1 U/mg at 80 to 100 mm Hg. Transduction
with 1 108 pfu/mL of AdhpAP increased the AP activity
to 5.9  1.4 U/mg and peaked at 30.6  9.7 U/mg with
1  109 pfu/mL of AdhpAP (n  6; P  .05; Fig 5, A).
However, transduction efficiency with an instillation pres-
sure of 80 to 100 mm Hg at 1 109 pfu/mL decreased the
AP activity to 10.9  2.6 U/mg (n  7; P  .01).
All carotid artery grafts that were transduced with Adh-
pAP also had increased AP activity over control grafts. The
AP activity of control arteries treated at 0 mm Hg, and 80
to 100 mm Hg, was 0.6  0.1 U/mg. Transduction with
1  108 pfu/mL of AdhpAP increased the AP activity to
4.4 1.9 U/mg and peaked at 32.8 9.9 U/mg with 5
109 pfu/mL of AdhpAP (n  6; P  .05). In contrast to
vein grafts, transduction efficiency with an instillation pres-
sure of 80 to 100 mm Hg at 5 109 pfu/mL increased the
AP activity to 63.4  20.5 U/mg (n  8; P  .05; Fig 5,
B).
DISCUSSION
In summary, the significant findings of these studies
are: 1, high transduction efficiency can be achieved with
adenoviral-mediated gene transfer in venous and arterial
grafts; 2, an instillation pressure of 80 to 100 mm Hg
decreased transduction efficiency for venous grafts yet in-
creased transduction efficiency for arterial grafts at certain
titers; and 3, maximal gene transfer to the graft lumen can
be achieved with lower adenoviral titers than are needed to
produce maximal transmural gene transfer. Therefore,
transduction conditions can be adjusted to achieve site-
specific gene transfer depending on the goal of the experi-
ment.
Somatic gene transfer to vascular autografts or allo-
grafts is one potential method to decrease the rate of
thrombosis, intimal hyperplasia, recurrent atherosclerosis,
or transplant rejection. Adenoviral-mediated gene transfer
Fig 4. Effect of adenoviral titer and instillation pressure on percent adventitial area stained of porcine venous and
arterial grafts. A, Venous grafts, P  .05. B, Arterial grafts, P  .05.
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of vascular grafts has been established as a viable method for
gene transfer with high transduction efficiency. Transduc-
tion efficiency of adenoviral vectors to vascular cells in vitro
is affected with adenoviral titer and duration of expo-
sure.10-12 Transduction efficiency to vascular grafts, in-vivo
and ex-vivo, is also dependent on adenoviral titer13,14 and
duration of exposure.15 However, adenoviral vectors have a
high specificity for endothelial cells13 and do not transduce
the media of a normal blood vessel wall easily.16 Schulick
and associate’s13 study of adenoviral transduction efficiency
in normal uninjured rat carotid arteries supports our find-
ings in porcine carotid arteries. They reported a maximum
endothelial cell transduction rate of 34% with occasional
smooth muscle cell transduction. However, gene transduc-
tion was performed at room temperature for 20 minutes
and vessels were distended without intraluminal pressure
monitoring.
We found a decrease in luminal transduction to arterial
grafts at the highest adenoviral titer used (1  1010 pfu/
mL), which approached but did not reach statistical signif-
icance (P .06). This trend may be the result of adenoviral
toxicity or endothelial cell loss. Our results are supported
by Schulick et al13 who found a decrease in recombinant
gene expression and endothelial denudation with high
adenoviral titers. We similarly found a decrease in luminal
transduction to venous grafts associated with high adeno-
viral titers. However, the maximum transfection was
achieved with an adenoviral titer that was 50-fold less than
that for arterial grafts as determined with total graft activity.
Venous grafts may be more susceptible to adenoviral tox-
icity because of the thinness of the vessel wall or the injury
caused during harvest of the vessel or both. Furthermore,
an instillation pressure of 80 to 100 mm Hg may have
increased the injury and therefore decreased transmural
Fig 5. Effect of adenoviral titer and instillation pressure on AP activity on porcine venous and arterial grafts. A, Venous
grafts, *P  .05 versus 108 pfu/mL at 0 mm Hg and 5  109 pfu/mL at 0 mm Hg; P  .05 versus 109 pfu/mL at
0 mm Hg. B, Arterial grafts, *P .05 versus 108, 109, and 1010 pfu/mL at 0 mm Hg; P .05 versus 5 109 pfu/mL
at 0 mm Hg.
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transduction (with 1  109 pfu/mL of AdhpAP). Unex-
pectedly, maximum transmural transduction efficiency for
venous grafts did not correlate with luminal transduction.
The reason for this finding is multifactorial: venous endo-
thelial cells may be more vulnerable to adenoviral toxicity
than smooth muscle cells. Consequently, there may have
been loss of endothelial cell transduction yet an increase in
transduction of smooth muscle cells in the media and
adventitia at the optimal titer. Given that no difference in
percent area stained was documented, the increase in activ-
ity is indicative of the total cellular protein production, not
the percent of cells transduced. Even though other vectors,
such as adenoassociated virus or plasmids alone, may have
fewer toxic effects or longer durability of expression, their
transfection efficiencies are substantially lower than that of
adenoviral vectors.
Previous studies in injured arteries have shown im-
proved smooth muscle cell transduction efficiency with
balloon delivery devices, endothelial disruption,17 balloon
injury of arterial walls,18 and pressurization of the vessel
during viral transduction.16 These studies are relevant for
gene transfer to sites of clinical arterial injury, such as
balloon angioplasty. Our study focused on gene transfer to
undamaged arterial and venous conduits, such as saphe-
nous vein and internal mammary artery used for aortocoro-
nary grafting. We found conditions that improved trans-
duction efficiency in the arterial grafts were different from
venous grafts. Our results of decreasing adenoviral trans-
duction efficiency in venous grafts with high instillation
pressures also are supported by Kibbe et al.3 They showed
decreased gene expression of nitric oxide synthase when
pressure was used in adenoviral-mediated gene transfer,
although precise pressure measurements were not per-
formed.
This is the first study to study the effect of instillation
pressure and adenoviral titer on gene transfer efficiency to
venous and arterial grafts ex-vivo. The finding that distinct
transduction conditions are necessary for optimal gene
transfer in veins and arteries reinforces the need to optimize
transduction conditions of vascular grafts on the basis of the
desired site of expression of the adenoviral transgene. Dif-
ferent viral titers and instillation pressures are necessary
even in the same type of graft (eg, veins) to generate either
maximal endothelial transduction or greatest total graft
transgene expression. Thus, the maximum endothelial ex-
pression may be the goal for the prevention of platelet
aggregation; conversely, the maximum transgene protein
production may be desired for the prevention of allograft
rejection.
We determined that transduction efficiency with a sin-
gle reporter virus and other adenoviral vectors may show
different patterns of expression on the basis of the toxicity,
intracellular processing, and secretion of the transgene
protein. The striking differences in endothelial transduc-
tion and total graft transgene activity noted with varying
titers and instillation pressures suggest that controlling and
optimizing these experimental conditions will play an im-
portant role in vascular gene therapy.
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